Below are current clinical trials.81 studies in Breast Clinic
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to culture human mammary cells to identify cellular characteristics associated with lobular involution status.
Rochester, Minn., Eau Claire, Wis., La Crosse, Wis.
The purpose of this study is to evaluate how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
To purpose of this study is to evaluate the change of vulvovaginal symptoms score from baseline to 6 months in premenopausal women with stage 0-III breast cancer treating with ovarian suppression in combination with aromatase inhibitors.
The purpose of this study is to determine if the use of Gilenya® can reduce neuropathy caused by paclitaxel.
Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.
Rochester, Minn., Scottsdale/Phoenix, Ariz.
This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2) result in fewer patients with on therapy Ki67>10% compared to historical control.
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
The primary purpose of this study is to assess the anti-tumor activity of estradiol in patients with locally advanced or metastatic triple negative breast cancer (TNBC) that expresses estrogen receptor beta (ERβ) (>25% moderate or strong nuclear staining) and who have had prior receipt of taxane and anthracycline based chemotherapy.
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2).
In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC.
Nov. 19, 2019
- National Accreditation Program for Breast Centers. American College of Surgeons. https://www.facs.org/quality-programs/napbc. Accessed Feb. 7, 2019.
- Breast SPOREs. National Cancer Institute. https://trp.cancer.gov/spores/breast.htm. Accessed Feb. 7, 2019.
- Find an NCI-designated cancer center. National Cancer Institute. https://www.cancer.gov/research/nci-role/cancer-centers/find. Accessed Feb. 7, 2019.